Company intelligence / Profile preview

PharmaMatrix

Lucama, North Carolina, United Statespharmamatrix.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Consulting Company: Provides technical, commissioning, validation, and calibration services to pharmaceutical manufacturers. Drug Development Entity ("PharmaMatrix" with CCI program): Lead compound CCI‑001 is in Phase 1 trials targeting bladder cancer by inhibiting βIII-tubulin; preclinical data show tumor growth inhibition with fewer side effects than traditional chemotherapy.

Therapeutic areas: Oncology
Modalities: small molecules (e.g., colchicine derivatives)
Industry: Biotech

Drug pipeline

1 asset

CCI-001

Phase 1

Indications: Bladder cancer, Adenocarcinoma of lung, Biliary tract neoplasms, Pancreatic cancer, Ovarian cancer, Cervical cancer, Endometrial cancer

Beyond the preview

Go deeper on PharmaMatrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaMatrix.

Explore the full profile